Li Chenggang, Zhao Zhiming, Zhou Zhipeng, Liu Rong
Department of Surgical Oncology, Chinese PLA General Hospital, 28#, Fuxing Road, Beijing, 100853, People's Republic of China.
Dig Dis Sci. 2016 Mar;61(3):767-73. doi: 10.1007/s10620-015-3931-2. Epub 2015 Oct 24.
Pyruvate kinase isoenzyme M2 (PKM2) is an essential enzyme involved in the regulation of aerobic glycolysis in cancer cells and promotes the translation between glycolytic flux and biosynthesis of cellular building blocks.
Our present study aims to explore the expression pattern and underlying cellular functions of PKM2 in pancreatic ductal adenocarcinoma (PDAC) under metabolic stress.
Oncomine database and a tissue microarray (n = 90) were used to investigate the expression pattern of PKM2 and its clinicopathological findings. In vitro proliferation, apoptosis and invasion assays were used to determine the role and related mechanism of PKM2 in PDAC.
Data from Oncomine database and our tissue microarray show that PKM2 is significantly elevated in PDAC specimens compared with the corresponding normal tissues. Kaplan-Meier survival analysis shows that higher expression of PKM2 is closely correlated with a poor prognosis of patients with PDAC. Under metabolic stress, suppression of PKM2 expression in PANC-1 and AsPC-1 cells results in decreased cell survival, increased caspase-3/7 activity, and reduced invasive potential, and these effects can be reversed by reintroduction of PKM2. Furthermore, sh-PKM2 cells show a significant decreased Warburg effect compared with sh-Ctrl cells as demonstrated by reduced glucose consumption and lactate production. Treatment with 2-deoxy-D-glucose, a glycolysis inhibitor, completely blocks the influences of PKM2 on cell survival and invasion.
Our study reveals that silencing of PKM2 exhibits a tumor-suppressive role through altered Warburg effect and suggests that targeting PKM2 might serve as a potential therapeutic target for PDAC.
丙酮酸激酶同工酶M2(PKM2)是一种参与癌细胞有氧糖酵解调节的关键酶,可促进糖酵解通量与细胞结构单元生物合成之间的转换。
本研究旨在探讨代谢应激下PKM2在胰腺导管腺癌(PDAC)中的表达模式及其潜在的细胞功能。
利用Oncomine数据库和组织芯片(n = 90)研究PKM2的表达模式及其临床病理特征。采用体外增殖、凋亡和侵袭实验来确定PKM2在PDAC中的作用及相关机制。
Oncomine数据库和我们的组织芯片数据显示,与相应正常组织相比,PKM2在PDAC标本中显著升高。Kaplan-Meier生存分析表明,PKM2的高表达与PDAC患者的不良预后密切相关。在代谢应激下,抑制PANC-1和AsPC-1细胞中PKM2的表达会导致细胞存活率降低、caspase-3/7活性增加以及侵袭能力降低,而重新引入PKM2可逆转这些效应。此外,与sh-Ctrl细胞相比,sh-PKM2细胞的瓦伯格效应显著降低,表现为葡萄糖消耗和乳酸生成减少。用糖酵解抑制剂2-脱氧-D-葡萄糖处理可完全阻断PKM2对细胞存活和侵袭的影响。
我们的研究表明,沉默PKM2通过改变瓦伯格效应发挥肿瘤抑制作用,并提示靶向PKM2可能是PDAC的潜在治疗靶点。